STOCK TITAN

Mirum Pharmaceuticals (MIRM) Financials

MIRM NASDAQ
Trailing 12 months to September 30, 2026
Revenue $670.8M +42.2% YoY
Net Income -$903.9M n/m YoY
EPS (Diluted) -$15.48 n/m YoY
Free Cash Flow -$273.9M -717.9% YoY
Market Cap $6.3B as of Nov 20, 2026
Price / Sales 9.4x on $670.8M revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book n/m negative shareholder equity, so no book multiple, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MIRM SEC filings page.

Mirum Pharmaceuticals, Inc. (MIRM) reported $670.8M in revenue over the twelve months to Sep 30, 2026, up 42.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MIRM FY2025

Revenue growth is beginning to absorb operating costs, but rising receivables and current liabilities make cash conversion the key operating signal.

FY2025 operating cash flow reached $56M despite a net loss of $23M, marking a meaningful improvement in earnings quality. Free cash flow was $55M because capital expenditures were only $954K, so reported cash generation is currently coming from operations rather than heavy reinvestment.

Revenue reached $521M in FY2025 while the operating loss narrowed to $22M, showing that increased scale is absorbing more of the company’s operating cost base. Still, SG&A consumed 49.3% of revenue and R&D consumed 35.7%, leaving the business expense-heavy even as losses approach break-even.

Receivables grew 57.5% while current liabilities grew 62.6%, indicating that expansion is tying more resources to both customer balances and near-term obligations. A current ratio of 2.7x and debt-to-equity of 1.0x show measurable liquidity and leverage, but the balance sheet is becoming more dependent on managing working capital as sales scale.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 73 / 100
Financial Health Score 73/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Mirum Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
87

Mirum Pharmaceuticals, Inc. held $391.4M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $55.8M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Mirum Pharmaceuticals, Inc. scores 87/100 among other emerging companies.

Dilution
51

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Mirum Pharmaceuticals, Inc. scores 51/100 on it among other emerging companies.

R&D Intensity
66

Mirum Pharmaceuticals, Inc. spent $186.2M on research and development in fiscal year 2025, which was 34.3% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Mirum Pharmaceuticals, Inc. scores 66/100 among other emerging companies.

Revenue Progress
83

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Mirum Pharmaceuticals, Inc. scores 83/100 on it among other emerging companies.

Burn Trend
96

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Mirum Pharmaceuticals, Inc. scores 96/100 on it among other emerging companies.

Balance Sheet
54

Mirum Pharmaceuticals, Inc.'s cash, cash equivalents and investments came to $391.4M at the end of fiscal year 2025, against $528.1M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Mirum Pharmaceuticals, Inc. scores 54/100 among other emerging companies.

Altman Z-Score Safe
7.04

Mirum Pharmaceuticals, Inc. scores 7.04, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $6.3B against total liabilities of $528.1M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
5/8

Mirum Pharmaceuticals, Inc. passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) passes.

Earnings Quality Mixed
N/A

Mirum Pharmaceuticals, Inc. reported a net loss of $23.4M while generating $55.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Mirum Pharmaceuticals, Inc. reported an operating loss of $22.1M against $14.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$185.7M
YoY+39.6%
QoQ+5.4%
5Y CAGR+106.1%

Mirum Pharmaceuticals, Inc. generated $185.7M in revenue in Q3 2026. This represents an increase of 39.6% from the same quarter a year earlier. Against the prior quarter it is up 5.4%.

EBITDA
-$52.9M
YoY-710.0%
QoQn/m

Mirum Pharmaceuticals, Inc.'s EBITDA was -$52.9M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 710.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$40.8M
YoY-1503.3%
QoQn/m
5Y CAGRn/m

Mirum Pharmaceuticals, Inc. reported a net loss of $40.8M in Q3 2026. This represents a decrease of 1503.3% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.87
YoY-1840.0%
QoQn/m
5Y CAGRn/m

Mirum Pharmaceuticals, Inc. earned -$0.87 per diluted share (EPS) in Q3 2026. This represents a decrease of 1840.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
-$5.6M
YoY-114.2%
QoQn/m
5Y CAGRn/m

Mirum Pharmaceuticals, Inc. recorded an outflow of $5.6M in free cash flow in Q3 2026, representing a cash shortfall after capex. This represents a decrease of 114.2% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$243.2M
YoY-13.8%
QoQ-26.5%
5Y CAGR+34.2%

Mirum Pharmaceuticals, Inc. held $243.2M in cash against $731.3M in long-term debt as of Q3 2026.

Shares Outstanding
65M
YoY+27.0%
QoQ+0.5%
5Y CAGR+16.3%

Mirum Pharmaceuticals, Inc. had 65M shares outstanding in Q3 2026. This represents an increase of 27.0% from the same quarter a year earlier. Against the prior quarter it is up 0.5%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Operating Margin
-32.2%
YoY-34.1pp
QoQ-8.0pp

Mirum Pharmaceuticals, Inc.'s operating margin was -32.2% in Q3 2026, reflecting core business profitability. This is down 34.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 8.0 percentage points.

Net Margin
-21.9%
YoY-24.1pp
QoQ+16.2pp

Mirum Pharmaceuticals, Inc.'s net profit margin was -21.9% in Q3 2026, showing the share of revenue converted to profit. This is down 24.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 16.2 percentage points.

Gross Margin

Not reported for Q3 2026.

Return on Equity

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$107.9M
YoY+151.2%
QoQ+19.2%
5Y CAGR+28.8%

Mirum Pharmaceuticals, Inc. invested $107.9M in research and development in Q3 2026. This represents an increase of 151.2% from the same quarter a year earlier. Against the prior quarter it is up 19.2%.

Capital Expenditures
$1.3M
YoY+597.9%
QoQ+5573.9%
5Y CAGR+135.5%

Mirum Pharmaceuticals, Inc. invested $1.3M in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 597.9% from the same quarter a year earlier. Against the prior quarter it is up 5573.9%.

Share Buybacks

Not reported for Q3 2026.

MIRM Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MIRM quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$185.7M+39.6%$176.2M+37.9%$159.9M+43.3%$148.9M+49.8%$133.0M+47.2%$127.8M+64.1%$111.6M+61.2%$99.4M+42.9%
R&D Expenses$107.9M+151.2%$90.5M+96.5%$97.9M+138.5%$56.1M+27.4%$43.0M+35.5%$46.1M+41.0%$41.0M+27.4%$44.0M+42.3%
SG&A Expenses$88.9M+43.5%$81.5M+28.7%$96.3M+66.9%$74.1M+30.4%$61.9M+22.5%$63.3M+28.6%$57.7M+26.4%$56.8M+23.1%
Operating Income-$59.7M-2395.3%-$42.5Mn/m-$789.5Mn/m-$4.6Mn/m$2.6Mn/m-$5.0Mn/m-$15.2Mn/m-$24.2Mn/m
EBITDA-$52.9M-710.0%-$35.6M-3436.6%-$782.6Mn/m$1.5Mn/m$8.7Mn/m$1.1Mn/m-$9.1Mn/m-$18.2Mn/m
Interest Expense$1.6M-55.5%$2.6M-27.1%$3.6M+0.6%$3.6M+0.5%$3.6M+0.6%$3.6M+0.6%$3.6M+0.5%$3.6M
Income Tax$538Kn/m$1.7M+320.1%$475K-53.8%$767Kn/m-$262K-175.5%$402K-36.7%$1.0M+64.9%-$576K-356.0%
Net Income-$40.8M-1503.3%-$67.2Mn/m-$790.2Mn/m-$5.7Mn/m$2.9Mn/m-$5.9Mn/m-$14.7Mn/m-$23.8Mn/m
EPS (Basic)-$0.62-1133.3%-$1.06n/m-$13.43n/m-$0.12n/m$0.06n/m-$0.12n/m-$0.30n/m-$0.49n/m
EPS (Diluted)-$0.87-1840.0%-$1.06n/m-$13.43n/m-$0.12n/m$0.05n/m-$0.12n/m-$0.30n/m-$0.49n/m
Diluted Shares (Avg)66M+15.9%63M+27.4%59M+20.4%N/A57M+19.3%50M+5.3%49M+4.2%N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

MIRM Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MIRM quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$1.0B+30.8%$1.0B+44.0%$890.9M+29.1%$842.8M+25.7%$785.1M+17.6%$725.8M+9.8%$690.2M+5.9%$670.8M+3.7%
Current Assets$586.6M+10.6%$636.3M+40.3%$569.4M+38.6%$549.7M+39.9%$530.6M+37.2%$453.4M+23.3%$410.8M+5.5%$392.8M+1.4%
Cash & Equivalents$243.2M-13.8%$330.7M+45.0%$324.9M+53.4%$296.7M+33.3%$282.0M+26.5%$228.1M-2.2%$211.8M-30.1%$222.5M-22.3%
Short-Term Investments$130.5M+39.5%$107.6M+40.7%$61.4M-6.8%$86.6M+49.9%$93.5M+52.1%$76.4M+69.4%$65.9Mn/m$57.8Mn/m
Inventory$25.5M+6.1%$25.8M+12.3%$25.5M+13.8%$24.9M+11.1%$24.0M+11.2%$22.9M+12.2%$22.4M+3.8%$22.4M+0.4%
Accounts Receivable$156.3M+45.9%$145.4M+36.1%$133.1M+38.9%$123.3M+57.5%$107.1M+56.3%$106.8M+76.8%$95.9M+74.3%$78.3M+15.2%
Long-Term Investments$126.8M+5032.3%$123.0M+619.0%$34.4M+64.3%$8.1M-35.3%$2.5M-73.5%$17.1M+0.2%$20.9Mn/m$12.5Mn/m
Total Liabilities$1.1B+119.2%$1.1B+124.2%$648.4M+41.9%$528.1M+18.6%$493.1M+13.1%$470.7M+9.0%$457.0M+9.5%$445.1M+11.9%
Current Liabilities$283.1M+76.5%$222.8M+53.9%$272.8M+113.9%$205.8M+62.6%$160.4M+38.5%$144.8M+28.9%$127.6M+20.5%$126.6M+45.4%
Non-Current Liabilities$797.7M+139.8%$832.6M+155.5%$375.6M+14.0%$322.3M+1.2%$332.7M+3.9%$325.9M+2.0%$329.4M+5.8%$318.6M+2.5%
Long-Term Debt$731.3M+136.4%$750.1M+142.8%$310.3M+0.6%$309.8M+0.6%$309.4M+0.6%$308.9M+0.6%$308.5M+0.5%$308.1M+0.5%
Total Equity-$54.2M-118.6%-$10.4M-104.1%$242.5M+4.0%$314.7M+39.5%$292.0M+25.9%$255.2M+11.4%$233.3M-0.6%$225.6M-9.3%
Retained Earnings-$1.6Bn/m-$1.5Bn/m-$1.5Bn/m-$667.5Mn/m-$661.8Mn/m-$664.7Mn/m-$658.9Mn/m-$644.2Mn/m

Not reported in any period shown, so not listed: Goodwill.

MIRM Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MIRM quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$4.3M-110.9%-$44.3M-467.5%-$228.8Mn/m$6.1Mn/m$39.7M+896.0%$12.0Mn/m-$2.0M-112.9%-$5.1Mn/m
Depreciation & Amortization$6.9M+13.6%$6.9M+14.5%$6.9M+13.6%$6.1M+0.3%$6.1M+0.1%$6.1M+3.5%$6.1M+6.9%$6.1M+10.2%
Stock-Based Compensation$33.3M+83.8%$30.6M+65.6%$36.2M+129.1%N/A$18.1M+52.2%$18.5M+56.0%$15.8M+38.0%N/A
Capital Expenditures$1.3M+597.9%$23K-81.7%$664K+1519.5%$600K+2900.0%$187K+3.3%$126K-83.8%$41K+215.4%$20Kn/m
Free Cash Flow-$5.6M-114.2%-$44.3M-471.6%-$229.4Mn/m$5.5Mn/m$39.5M+938.5%$11.9Mn/m-$2.0M-113.2%-$5.1Mn/m
Investing Cash Flow-$28.9Mn/m-$160.0Mn/m-$11.6Mn/m$1.0M+56.9%-$2.2Mn/m-$6.6Mn/m-$16.1Mn/m$641Kn/m
Financing Cash Flow-$54.3M-437.6%$211.4M+2333.7%$270.1M+4147.2%$9.0M+68.5%$16.1M+316.7%$8.7M+19.2%$6.4M+427.7%$5.3M+200.5%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

MIRM Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MIRM quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Margin-32.2%-34.1pp-24.1%-20.2pp-493.8%-3.1%+21.3pp2.0%+16.0pp-3.9%+27.2pp-13.6%+24.6pp-24.4%+22.5pp
Net Margin-21.9%-24.1pp-38.1%-33.6pp-494.2%-3.9%+20.1pp2.2%+17.9pp-4.6%+27.1pp-13.2%+23.4pp-23.9%+27.3pp
Return on EquityN/AN/A-325.9%-319.6pp-1.8%+8.7pp1.0%+7.1pp-2.3%+8.5pp-6.3%+4.5pp-10.5%+3.8pp
Return on Assets-4.0%-4.3pp-6.4%-5.6pp-88.7%-86.6pp-0.7%+2.9pp0.4%+2.5pp-0.8%+2.9pp-2.1%+1.8pp-3.5%+2.0pp
Current Ratio2.07-1.2x2.86-0.3x2.09-1.1x2.67-0.4x3.310.0x3.13-0.1x3.22-0.5x3.10-1.3x
Debt-to-EquityN/AN/A1.280.0x0.98-0.4x1.06-0.3x1.21-0.1x1.320.0x1.37+0.1x
Liabilities-to-EquityN/AN/A2.67+0.7x1.68-0.3x1.69-0.2x1.840.0x1.96+0.2x1.97+0.4x
Asset Turnover0.180.0x0.170.0x0.180.0x0.180.0x0.170.0x0.18+0.1x0.16+0.1x0.150.0x
FCF Margin-3.0%-32.7pp-25.1%-34.4pp-143.5%3.7%+8.8pp29.7%+25.5pp9.3%+15.2pp-1.8%-23.8pp-5.1%+18.8pp

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Mirum Pharmaceuticals, Inc. MIRM FY2025 $521.3M -$23.4M -4.5% $6.3B 73/100
Arrowhead Research Corporation ARWR FY2026 $450.8M -$724.2M N/A $5.8B 73/100
Belite Bio, Inc BLTE FY2025 N/A -$77.6M N/A $5.2B —
CG Oncology, Inc. CGON FY2025 $4.0M -$161.0M N/A $7.1B 62/100
ImmunityBio, Inc. IBRX FY2025 $113.3M -$351.4M N/A $6.4B 51/100
Ligand Pharmaceuticals Inc. LGND FY2025 $268.1M $124.5M 46.4% $5.7B 68/100

Frequently Asked Questions

Mirum Pharmaceuticals, Inc. (MIRM) reported $521.3M in total revenue for fiscal year 2025. This represents a 54.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Mirum Pharmaceuticals, Inc. (MIRM) revenue grew by 54.7% year-over-year, from $336.9M to $521.3M in fiscal year 2025.

No, Mirum Pharmaceuticals, Inc. (MIRM) reported a net loss of $903.9M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $23.4M, with a net profit margin of -4.5%.

Mirum Pharmaceuticals, Inc. (MIRM) reported diluted earnings per share of -$0.47 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Mirum Pharmaceuticals, Inc. (MIRM) had EBITDA of $2.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Mirum Pharmaceuticals, Inc. (MIRM) had $296.7M in cash and equivalents against $309.8M in long-term debt.

Mirum Pharmaceuticals, Inc. (MIRM) had an operating margin of -4.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Mirum Pharmaceuticals, Inc. (MIRM) had a net profit margin of -4.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Mirum Pharmaceuticals, Inc. (MIRM) has a return on equity of -7.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Mirum Pharmaceuticals, Inc. (MIRM) generated $54.9M in free cash flow during fiscal year 2025. This represents a 488.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Mirum Pharmaceuticals, Inc. (MIRM) generated $55.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Mirum Pharmaceuticals, Inc. (MIRM) had $842.8M in total assets as of fiscal year 2025, including both current and long-term assets.

Mirum Pharmaceuticals, Inc. (MIRM) invested $954K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Mirum Pharmaceuticals, Inc. (MIRM) invested $186.2M in research and development during fiscal year 2025.

Mirum Pharmaceuticals, Inc. (MIRM) had 60M shares outstanding as of fiscal year 2025.

Mirum Pharmaceuticals, Inc. (MIRM) had a current ratio of 2.67 as of fiscal year 2025, which is generally considered healthy.

Mirum Pharmaceuticals, Inc. (MIRM) had a debt-to-equity ratio of 0.98 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Mirum Pharmaceuticals, Inc. (MIRM) had a liabilities-to-equity ratio of 1.68 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Mirum Pharmaceuticals, Inc. (MIRM) had a return on assets of -2.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Mirum Pharmaceuticals, Inc. (MIRM) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $6.3B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Mirum Pharmaceuticals, Inc. (MIRM) trades at 9.4x sales, its market capitalization divided by $670.8M revenue, trailing 12 months to September 30, 2026. The market capitalization is $6.3B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Mirum Pharmaceuticals, Inc. (MIRM) has an Altman Z-Score of 7.04, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Mirum Pharmaceuticals, Inc. (MIRM) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Mirum Pharmaceuticals, Inc. (MIRM) reported a net loss of $23.4M while generating $55.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Mirum Pharmaceuticals, Inc. (MIRM) reported an operating loss of $22.1M against $14.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Mirum Pharmaceuticals, Inc. (MIRM) scores 73 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top